Summary. -A panel of 17 monoclonal antibodies (MAbs) against highly pathogenic avian influenza virus (HPAIV) A/Duck/Novosibirsk/56/05 A/H5N1 (subclade 2.2) isolated in Russian Federation was developed. Immunoblot analysis showed that 12 MAbs were specific for the hemagglutinin (HA) and 5 MAbs for nucleoprotein (NP). All anti-HA MAbs were reactive in ELISA and immunofluorescence (IF) test and 10 of them were reactive in hemagglutination-inhibition (HI) and neutralization tests. Quantitative competitive ELISA revealed that anti-HA MAbs recognized at least 4 non-overlapping antigenic determinants and anti-NP MAbs recognized at least 3 non-overlapping antigenic determinants. Four sandwich ELISA procedures were developed using the obtained MAbs. These procedures are useful for 1) identification of avian, human, and swine influenza A viruses, 2) differentiation of avian influenza virus (AIV) from human and swine influenza viruses, 3) differentiation of AIV H5 from other AIV subtypes, and 4) differentiation between 2.2 and 2.3.2 subclades of H5N1 influenza viruses. Prophylactic and therapeutic efficacy of anti-HA MAbs with high neutralization activity was tested in BALB/c mice. A complete protection was achieved by single injection of MAbs (20 mg/kg) 24 hrs before challenge with 10 LD 50 of HPAIV H5N1. Therapeutic efficacy was 90% that was similar to those of Rimantadine and Tamiflu.
Introduction
Avian influenza A viruses (H5N1) have caused epizooties in Southeast Asia and other regions. Some variants of H5N1 virus induced serious infections in humans with high lethality. WHO reported 295 deaths out of 499 cases (WHO, 2010) . The majority of H5N2 and H5N3 viruses isolated in Russian Federation from wild birds and poultries showed low pathogenicity. For the first time HPAIVs H5N1 were isolated in Western Siberia in 2005. In the years 2006-2007 these viruses circulated in European and Asian part of Russian Federation. Phylogenetic analysis showed that they belonged to the Qinghai type, subclade 2.2 (Ľvov and Kaverin, 2008) . New strains of HPAIV H5N1 isolated in [2008] [2009] in Western Siberia from wild birds and poultries were attributed to the subclade 2.3.2 (Ľvov et al., 2008) .
At present AIVs circulating in Southeast Asia are thoroughly studied Peiris et al., 2007) . Analysis of RNA and investigation of antigenic and three-dimensional structure of H5 hemagglutinin revealed considerable difference between low pathogenic AIV (LPAIV) strain А/Duck/ Singapore/3/97 and HPAIV strain A/Vietnam/1203/04 isolated from humans (Webster and Govorkova, 2006) . Rapid and sensitive laboratory and field tests for the diagnosis of HPAIV H5N1 are essential for the disease control. MAbs against the currently circulating H5N1 viruses are necessary for analysis of antigenic structure and diagnosis. Anti-HA MAbs to the different clades of H5N1 influenza viruses were successfully used for the HA mapping of viruses isolated in Southeast Asia He et al., 2007; Kaverin et al., 2007; Wu et al., 2008; Du et al., 2009; Ho et al., 2009 ). MAbs to Qinghai-type H5N1 have not been prepared up till now.
This study reports epitope specificity of 17 MAbs to HPAIV H5N1 A/Duck/Novosibirsk/56/05 (subclade 2.2), their virus-neutralizing activity in vitro and protective efficacy in vivo.
Materials and Methods
Viruses. Influenza viruses used in this study are listed in Table  2 and 4. All viruses were obtained from the Virus collection of the D.I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, Moscow, Russian Federation. The viruses were propagated for 48 hrs in the allantoic cavities of 10-day-old embryonated chicken eggs at 37°C. Strain A/Duck/Novosibirsk/56/05 was propagated in the pig embryo kidney (PEK) cells, concentrated, purified using a sucrose density gradient, and inactivated by treating with β-propiolacton (Kushch et al., 2008) . This virus was used as an antigen for immunization of mice and production of MAbs. In addition, it was used also in some immunological assays.
Production of MAbs. Preparation of MAbs against HPAIV A/Duck/Novosibirsk/56/05 (H5N1) was described previously (Kushch et al., 2008) . Large quantities of MAbs were prepared as ascitic fluid. Immunoglobulins were precipitated with ammonium sulphate and purified using Protein A-Sepharose CL-4B column (Sigma). Purified MAbs were conjugated with horseradish peroxidase (HRP, Sigma) by the periodate method (Nakane and Kawaoi, 1974) .
Isotyping of MAbs. Isotyping was performed by using a MouseHybridoma-Subtyping Kit (Boehringer Mannheim).
HI test was performed with human red blood cells (group 0) by standard method (WHO, 2004) . Influenza virus doses presented 8 U.
Neutralization assay. MAb-containing ascitic fluids were inactivated, serially diluted, and incubated with 100 TCID 50 of HPAIV A/Duck/Novosibirsk/56/05 for 2 hrs at 37°С and added to the PEK cell monolayers. CPE was observed after 72-96 hrs, when the maximum CPE was visible in the infected cell culture without MAbs. The highest dilution of MAb showing 50% CPE was scored as the neutralization titer.
Indirect ELISA. The procedure for indirect ELISA was described previously (Masalova et al., 2002) . Briefly, 96-well plates (NUNC) were sensitized with 2 µg/ml of A/Duck/Novosibirsk/56/05 antigen (overnight, room temperature) and incubated with serially diluted MAbs, washed, and incubated with HRP-conjugated rabbit antimouse Ig (DAKO). The enzyme activity was determined using the substrate 3,3ʹ,5,5ʹ-tetramethylbenzidin (Sigma) with H 2 O 2 at 450 nm. Reciprocal dilution with A 450 2-fold as high as that of A 450 of negative control (anti-hepatitis C MAbs with the same Ig subtype) was taken as MAb titer.
Competitive ELISA. Epitope specificities of the MAbs were analyzed in competitive ELISA as described elsewhere (Masalova et al., 2002) . The A/Duck/Novosibirsk/56/05 antigen was immobilized on 96-well ELISA plates (2 µg/ml) and incubated with 100 µg/ml MAbs (or ascitic fluids in dilution 1:100) overnight at 4°С. Serial dilutions of competing MAbs were used in some experiments. HRP-labeled MAbs were added in dilutions providing A 450 = 1.0-1.5 upon interaction with influenza virus in the absence of competing MAbs and incubated for 1 hr at 37°С. A 450 determination was performed and the results were expressed as inhibition degree in % of the binding of the conjugated MAbs with virus in the presence of competing unlabeled MAbs.
Sandwich ELISA. MAbs (5 µg/ml in PBS) were immobilized on plastic plates (overnight, room temperature) and after washing were incubated for 2 hrs at 37°С with A/Duck/Novosibirsk/56/05 antigen or virus-containing fluids, then with HRP-labeled MAbs (1 hr at 37°С). Results were regarded positive if A 450 was greater than cut-off value that was calculated as the mean of negative controls (blocking buffer without virus, native allantoic fluid or culture medium) plus two standard deviations.
Immunoblot analysis. A/Duck/Novosibirsk/56/05 antigen was subjected to 10% SDS-PAGE and separated under both reducing and non-reducing conditions. Separated proteins were electroblotted onto nitrocellulose membrane (Schleicher&Schuell). After blocking, the blots were incubated with ascitic fluid or hybridoma supernatant in PBST with 5% nonfat milk for 2 hrs at and then incubated with HRP-conjugated rabbit anti-mouse Ig for 1 hr at room temperature. The blots were developed by incubation with 3, 3ʹ-diaminobenzidine (DAB, Sigma) and H 2 O 2 as described (Masalova et al., 2002) . Dot blot analysis. Influenza viruses were adsorbed onto nitrocellulose membrane (Schleicher&Shuell) using a Bio-Dot apparatus (BioRad). The membranes were incubated with MAbs, HRP-conjugated rabbit anti-mouse Ig and DAB as described for immunoblot analysis. The reaction sensitivity and specificity were determined using serial dilutions of A/Duck/Novosibirsk/56/05 antigen and allantoic fluids containing various influenza viruses, respectively.
IF test. Acetone fixed PEK cells grown on slides and infected with HPAIV A/Duck/Novosibirsk/56/05 were incubated with MAbs for 1 hr at 37°С. Slides were washed with tap water. The secondary FITCconjugated rabbit anti-mouse immunoglobulin (DAKO) diluted 1:50 in PBS with 0.3% Evans blue was incubated for 1 hr at 37°С. The results were observed under UV microscope (Olympus).
Determination of prophylactic and therapeutic efficacies of MAbs was done in BALB/c mice aged 4 to 6 weeks. Twenty mice were anesthetized with ketamine-xylazine and intranasally infected with 10 LD 50 in 50 µl of PBS of HPAIV А/Chicken/Kurgan/Russia/2/05 (H5N1). LD 50 was determined by the method of Reed and Muench (1938) .
To determine the prophylactic efficacy of MAb 4F11, groups of mice (n = 10) were pretreated intraperitoneally with 2, 10, or 20 mg/kg of MAb in 100 µl of PBS 24 hrs prior to the viral challenge. The control group (n = 20) received 100 µl of PBS. After 24 hrs, the mice were challenged with 10 LD 50 of HPAIV H5N1. To determine therapeutic efficacy of MAb 4F11, each group of mice (n = 10) was treated intraperitoneally with 2, 10, and 20 mg/kg of MAb in 100 µl of PBS 24 hrs after viral challenge. The control group (n = 20) received 100 µl of PBS. Rimantadine (Rozfarm, Russian Federation) and Oseltamivir (Tamiflu ® , Roche, Switzerland) were used as controls. They were administered daily for 5 days before infection perorally at concentrations of 16 and 13 mg/kg in 50 µl of PBS (prophylactic study, n = 20). In addition, the mice were administered 30 and 25 mg/kg daily 5 days after infection (therapeutic study, n = 20). The mice were observed daily for 21 days after the viral challenge to monitor mortality.
Statistical analysis. Means and standard deviations of A 450 determinations were calculated using Statistica 6.0 software. The significance of differences was evaluated by Fisher's test. The differences were regarded as statistically significant at P <0.05.
Results

General characteristics of MAbs
A panel of hybridoma clones secreting MAbs to the HPAIV A/Duck/Novosibirsk/56/05 (H5N1) was generated by screening supernatants in ELISA and HI test. The highest antibody titers in these assays were obtained with 17 MAbs that were selected for subsequent experiments (Kushch et al., 2008) . The characteristics of previously received 14 MAbs and 3 new MAbs are summarized in Table 1 
Reactivity of MAbs in immunoblot analysis
The specific recognition of both native and denatured NP of HPAIV A/Duck/Novosibirsk/56/05 by MAbs 4H4, 2E6, 1G7, 1G8, and 2A5 was demonstrated in the immunoblot analysis ( Fig. 1 , Table 1 ). However, interaction of the majority of MAbs except 2A5 with NP was weak. Twelve MAbs were reactive with the non-cleaved HA0 molecule. Only 2 MAbs 3G5 and 5E5 recognized HA1. Remaining MAbs were nonreactive under the reducing conditions. (14) were prepared by Kushch et al. (2008) . Newly prepared MAbs (3) 
Reactivity of MAbs in competitive and sandwich ELISA
Epitope specificities of anti-HA MAbs were studied in competitive ELISA. The inhibition of interaction between HRP-conjugated Mabs and A/Duck/Novosibirsk/56/05 antigen by unlabeled MAbs was analyzed (Fig. 3a) . A topology of antigenic sites for these MAbs is schematically illustrated in Fig. 4 . Ten MAbs recognized at least 4 non-overlapping antigenic determinants I -IV (Fig. 4) . Six epitopes recognized by MAbs of group II are similar but not identical, as evidenced by non-symmetric competitive relations between these MAbs (Fig. 3a) . The same is true for the MAbs of group III (3G5 and 5E5). MAbs 4G10 and 7Е11 actively inhibited binding of conjugated MAbs of group I (4F11) and group II, although in both groups blocking was not symmetrical (Fig. 3a) .
In order to determine the epitope specificity of MAbs 4G10 and 7Е11 more accurately we analyzed concentration dependence of competition (Fig. 5) . When MAb 7Е11 was
Reactivity of MAbs in HI test
Anti-HA MAbs were analyzed in HI test with a wide spectrum of AIV А/Н5 (Table 2) 
Reactivity of MAbs in dot blot analysis
The MAbs reacted with A/Duck/Novosibirsk/56/05 antigen in dot blot analysis with detection limit 30-90 ng of viral protein. Anti-NP MAbs 1G7, 1G8, and 2A5 were reactive with all tested human, avian, and swine influenza A viruses, but MAbs 4H4 and 2E6 reacted only with AIV (Table 3 ). All anti-HA MAbs recognized only HPAIV H5N1 (subclade 2.2) and LPAIV H5N3 in the allantoic fluids. The differences in the reactivity of anti-HA MAbs with HPAIV H5N1 (subclade 2.3.2) were demonstrated. Only MAbs 2C6, 3G5, and 5E5 were able to recognize 2-3 of these viruses in dot blot analysis. None of the MAbs reacted with influenza B virus. Some patterns of reactivity of two MAbs 4G10 and 1G7 are shown in Fig. 2 . 
Influenza viruses are listed in Tables 2 and 4. Various combinations of MAbs were tested in sandwich ELISA in order to identify MAb pairs with the highest sensitivity of virus detection. More than 150 combinations of the MAbs as capture and detecting (HRP-conjugated) antibodies were analyzed. First, we evaluated detection limit for the homologous HPAIV A/Duck/Novosibirsk/56/05 antigen. The highest sensitivity (about 1 ng/ml viral protein) was observed with anti-NP MAbs: capture MAb 4H4 -detecting MAb 2A5. The combination of MAbs capture 1G7 -detecting 2A5 had a similar sensitivity. Sandwiches composed of anti-HA MAb combinations detected purified homologous virus with a lower sensitivity compared with the anti-NP MAb combinations. The highest sensitivity (about 5 ng/ ml viral protein) was observed using two compositions: capture MAb 5G9 -detecting MAb 4F11 and capture MAb 5E5 -detecting MAbs 4F11 and 5F12 combined.
The sensitivity and specificity of influenza viruses detection were analyzed in sandwich ELISA using allantoic fluids used as a competitor, 50% inhibition of binding between the virus and conjugated MAbs 4F11 and 7Е11 occurred at the MAb 7Е11 concentration of 2-3 μg/ml, and group II conjugated MAbs at 7Е11 concentrations of 10-20 μg/ml (Fig. 5a ). By contrast, MAb 4G10 employed as a competitor inhibited the binding of conjugated group II MAbs at the concentration of 0.04 μg/ml and that of MAbs 4F11 and 7Е11 at 7-20 μg/ml (Fig. 5b) . Thus, MAbs 7Е11 and 4G10 recognized partially overlapping antigenic sites on HA molecule. MAb 7Е11 demonstrated greater affinity for group I and MAb 4G10 for group II (Fig. 3, 4 , and 5).
Competitive analysis of anti-NP MAbs has shown that they recognize at least 3 non-overlapping antigenic determinants of the protein. One of them was recognized by MAbs 4H4 and 2E6, second one by MAbs 1G7 and 1G8, and the third one by MAb 2A5 (Fig. 3b) . It should be noted that MAbs 4H4 and 2E6 displayed non-symmetric inhibition of binding that pointed to the partial overlapping, but not to the same epitopes. To determine the sensitivity of sandwich ELISA, allantoic fluids containing various influenza viruses with known HA titer were serially diluted and tested in the sandwich ELISA. The comparison of viral titers in ELISA and HA test showed that the sensitivity of virus detection in the allantoic fluids by ELISA was 4 to 160-fold (mean 41-fold) higher than in the HA test (Fig. 6 ).
Prophylactic and therapeutic efficacies of MAb 4F11
High neutralizing MAb 4F11 was tested for prophylactic and therapeutic efficacy (Fig. 7) . To evaluate its prophylactic efficacy, the groups of experimental mice (n = 10) were treated with the indicated dosages of MAb 24 hrs prior to lethal virus challenge with 10 LD 50 of HPAIV H5N1 strain. The mice given low doses of MAb 4F11 (2 mg/kg bodyweight) demonstrated 50% protection effect (Fig. 7a) . Increased amounts of this MAb (10 mg/kg) protected 90% of mice from infection. Twenty mg/kg of MAb 4F11 completely protected mice from death and any clinical signs after challenge with the H5N1 strain. Tamiflu ® protected 65% (13/20) and Rimantadine 60% (12/20) of the treated mice. To evaluate therapeutic potential of MAb 4F11, the mice were treated with indicated doses of MAb 4F11 24 hrs after challenge with the virus. Two mg/kg and 10 mg/kg of MAb 4F11 provided 50% and 60% protection, respectively (Fig. 7b) . At the concentration 20 mg/kg, MAb 4F11 protected 90% of mice against 10 LD 50 of H5N1 strain. In therapeutic study Tamiflu ® protected 70% and Rimantadine 45% of mice. The differences between protective efficacy of MAb 4F11 at the highest concentration and Rimantadine were statistically significant both in prophylactic (P = 0.029) and therapeutic (P = 0.024) studies. Control mice (untreated with MAb) mice showed 100% mortality within 10 days after the viral challenge.
Discussion
HPAIVs H5N1 cause systemic disease of the wild birds and poultry with a high mortality (Spackman, 2008) . Avian influenza became a serious problem after direct transmission of AIV to the humans. High lethality was documented among humans in Hong Kong in the years 1997-1998 (Claas et al., 1998; Subbarao et al., 1998) . Studies of antigenic structure of AIV have shown that the viruses isolated during recent years differ considerably from those isolated previously Wu et al., 2008) . Therefore, the monitoring of H5N1 virus variations is necessary.
From the competitive analysis data we concluded that anti-HA MAbs characterized in this study were directed against at least 4 non-overlapping antigenic determinants on the HA molecule. Escape mutant mapping 7 out of 12 anti-HA MAbs has shown that the epitopes recognized by MAbs 5G9, 6E2, 5F12, 3G9, and 6F3 are located in an area adjacent to the antigenic site B in globular head of the HA molecule with antigenically relevant positions of amino acid residues 113, 115, 117, 118, 120, 121, 123, and 162 . The epitopes recognized by MAbs 4F11 and 7E11 were located in the site A (aa 141 and 139) (Rudneva et al., 2010) . Preliminary data have shown that MAb 4G10 recognized also the site A (145 aa) (I. Rudneva, personal communication) . Thus, a comparison of these data with those of competitive analysis indicated that the site II corresponded to the site B and the site I corresponded to the site A. It could be suggested that MAbs 7E11 and 4G10 partially overlapped both sites A and B on the HA molecule. We did not use Mabs 2C6, 7B3, 3G5, and 5E5 for the escape mutant selection, since these MAbs demonstrated low or no activity in HI test with wild type A/Mallard/10218/84 (H5N2) strain used to obtain the escape mutants. Two MAbs (3G5 and 5E5) did not react with H5 viruses in the HI and virus neutralization tests suggesting that they interacted with aa residues other than those forming the receptor-biding site of HA. Since the MAbs 2C6, 3G5, and 5E5 did not compete with the MAb of groups I and II (sites A and B) and differed from them in immunological and biological properties, we supposed that they were specific for other sites on the HA molecule. It was interesting that all MAbs reactive in HI and virus neutralization tests recognized the conformational epitopes and belonged to the IgG2a subtype. By contrast, MAbs 3G5 , and 5E5 reacted with these viruses in dot blot analysis. Thus, the epitopes recognized by these MAbs were the most conserved. Further investigation, however, is needed to determine the exact residues that constitute the 2C6, 3G5, and 5E5 epitopes. Taken together, these findings indicated that viruses H5N1 belonging to the subclade 2.3.2 had considerable antigenic change in sites A and B compared to the LPAIV H5N2 and A/H5N3 and HPAIV H5N1 of the subclade 2.2.
Rapid, early, and reliable detection of A/H5 viruses is the key issue in control of influenza disease. Since the majority of our MAbs displayed a high reactivity in immunochemical tests, they could be employed in the development of various immunoassays. All anti-HA and anti-NP MAbs differentiated between influenza A and B viruses. MAbs 2C6, 3G9, 6E2, and 5F12 that have shown high reactivity in IF test are prospective reagents for the direct virus detection or virus identification in specimens of infected birds, animals, and humans in rapid culture assay. These MAbs could be also suitable for the development of rapid test based on the dot blot assay and immunochromatography for the use in field.
Several sandwich ELISA procedures (antigen capture ELISA) based on anti-HA and anti-NP antibodies have been suggested for the detection of influenza viruses (Chomel et al., 1989; Hornsleth and Jankowski, 1990; Scalia et al., 1995; Tkáčová and Varečková, 1996; Varečková et al., 2001; Zhang et al., 2006; He et al., 2007; Yang et al., 2008; Du et al., 2009; Yang et al., 2009) . Various immunochemical properties and broad epitope specificity of MAbs analyzed in this study allowed us to develop several sandwich ELISAs for the detection of influenza A viruses including new pandemic H1N1 influenza viruses, for typing of AIV, and for differentiating HPAIV H5N1 of subclades 2.2 and 2.3.2. It should be noted that the use of anti-HA MAbs 2C6 and 5E5 against conserved epitopes and detecting combination of MAbs (4F11 + 5F12 + 2C6) to the non-overlapping antigenic determinants enhanced the sensitivity and specificity of sandwich ELISA. Viruses in allantoic fluid samples with HA titer 1:16-1:256 were detected in the dilution up to 1:10,000 that was several times higher than the sensitivity of other sandwich ELISAs (He et al., 2007; Ho et al., 2009) . However, further evaluation of the H5N1 sandwich ELISA using field samples is needed to determine sensitivity and specificity of the assay in a more quantitative way.
Special attention has been focused on the virus-neutralizing anti-HA antibodies. MAb 4F11 was tested in prophylactic and therapeutic experiments in the mice infected with 10 LD 50 HPAIV А/Chicken/Kurgan/Russia/2/05 (H5N1, subclade 2.2) that displayed antigenic properties similar to the HPAIV A/Duck/Novosibirsk/56/05 (Lvov and Kaverin, 2008) . This antibody was chosen since it neutralized most effectively a homologous virus in vitro (titer >1:20,000). A single intraperitoneal injection of 20 mg/kg MAb 4F11 produced 100% and 90% protective effects in prophylactic and therapeutic studies, respectively. However, this effect was dose-dependent. Similar results have been obtained also by other researchers. For example, passive immunization of mice with the anti-HA antibodies of different origins (murine, humanized, chimeric and human) produced various degree of protection against lethal doses of HPAIV H5N1 (Hanson et al., 2006; Chen et al., 2009; Koudstaal et al., 2009; Prabhu et al., 2009a, b; Sun et al., 2009) . The protective efficacy of MAb 4F11 was similar or higher than that of Tamiflu and Rimantadine. This finding opened prospects for the production of humanized antibodies based on this MAb for the prevention and therapy of disease caused by the H5N1 influenza virus in humans.
Thus, the panel of MAbs tested in this study could allow the detection of antigenically significant epitopes in НА of Н5 viruses, to develop immunoassays for rapid differential diagnosis of avian, animal, and human influenza A viruses, and to demonstrate a high prophylactic activity and therapeutic effectiveness. In addition, these MAbs can be used for the influenza A virus detection, analysis of the antigenic drift of H5 viruses, and for the design of effective measures needed for the prevention and therapy of influenza.
